NeON promotes new head, IPG bumps Lane upstairs

Share this article:
Interpublic Group promoted Matt Lane, co-founder and managing director of NeON, to a position at the holding company level. The agency's parent company, Draftfcb Healthcare, immediately named his successor.
Taking Lane's place at NeON is new managing director Mark Arnold, formerly SVP, managing supervisor at Omnicom's AgencyRx, said Dana Maiman, CEO of Draftfcb Healthcare. Before coming to AgencyRx, Arnold had been with Euro RSCG Life.
Arnold now joins NeON EVP, executive creative director Kevin McHale, who was brought on from Euro RSCG to lead creative in December.
In his new role, Lane will aid IPG with healthcare holding company consolidations, a new position. The network has been a beneficiary of the last three Big Pharma advertising business reviews: Merck's this past May, GlaxoSmithKline's in late 2010, and Johnson & Johnson's in 2008.
One of two Draftfcb Healthcare conflict shops, NeON services about 40 brand assignments from Pfizer, Boehringer Ingelheim and Gilead, with 100 employees working on digital promotion and traditional advertising as well as consulting.
Lane helped launch the agency in 2009 with a pair of brands from the roster of sister agency Area 23, where he had also been a managing director. He started his first agency after stints as a Pfizer sales rep and account manager at CDM.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?